Table 8.

Nootropics and Alzheimer’s disease

Reference	Title	Main results	Study type	Patients randomized
Alvarez et al28	Efficacy and safety of cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of cerebrolysin	Cerebrolysin is effective for global cognitive function and behavioral symptoms	Clinical trial, randomized, double-blind	133 patients
Plosker and Gauthier54	Cerebrolysin: a review of its use in dementia	Promising results with cerebrolysin in patients with Alzheimer’s disease	Review	NA
Akhondzadeh et al55	A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer’s disease	Provides preliminary evidence of a possible therapeutic effect of saffron extract in treatment of patients with mild-to moderate Alzheimer’s disease	Clinical trial, randomized, double-blind	54 patients
Schaeffer et al57	Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer’s disease	Phospholipase A2 could be a valid therapeutic strategy for cognitive enhancement in early-stage Alzheimer’s disease	Review	NA
Yurko-Mauro56	Cognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive decline	Docosahexaenoic acid has significant positive effects on verbal recognition memory	Clinical trial, randomized, double-blind	485 patients